A global tech and pharma supplier that introduced a generic equivalent to GE Healthcare’s Visipaque during the height of the 2022 contrast shortage has begun offering a substitute for Guerbet’s Dotarem.

An AI startup in the neuro-oncology space has received the government’s go-ahead to market software for analyzing certain fast-growing brain tumors on MRI.

GE Healthcare may ship its deep learning-based image reconstruction software called AIR Recon DL with new 3D capabilities, the company announced Sept. 29.

An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.

Patients with autoimmune hepatitis may be better monitored across disease stages by AI-augmented multiparametric MRI than by liver biopsy, as the imaging has proven less costly and is inherently less risky due to its noninvasiveness. 

A pharmaceutical compound approved 21 years ago to treat breast cancer in postmenopausal women is showing fresh promise as a therapy for glioblastomas. 

The boon comes in the form of greater brain cortical thickness observable on neonatal MRI two weeks after the baby enters the world.

The Sept. 21 announcement states that Gadopiclenol Injection—a highly stable macrocyclic gadolinium-based contrast agent—is approved for use in adult and pediatric patients aged 2 years and older during MRI exams.